Lexicon to Resubmit Sotagliflozin NDA for Type 1 Diabetes After FDA Feedback

 Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease

Resubmission is Anticipated Mid-2024

https://www.globenewswire.com/news-release/2024/03/11/2843620/0/en/Lexicon-Preparing-to-Resubmit-Sotagliflozin-NDA-for-Type-1-Diabetes-Following-Feedback-From-FDA.html